Pfizer Inc. is conducting the first-ever randomized clinical trial under an investigational new drug (IND) application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their proximity to clinical sites.

Novartis announced new data showing a significant improvement in both recurrence-free survival and overall survival for patients taking Glivec® (imatinib) for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (GIST) compared to one year of treatment.

Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading pharmaceutical company in China, jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture.

Bristol-Myers Squibb Company (NYSE:BMY) has entered in to a clinical collaboration agreement with Roche (SIX:RO; OTCQX:RHHBY) to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

Novartis will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).

AstraZeneca and Heptares Therapeutics have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs).

Sanofi (EURONEXT: SAN and NYSE:SNY) and Drugs for Neglected Diseases initiative (DNDi) announced a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries.